Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 361 companies set new 52-week lows.
Gamida Cell Priced 12.9M Share Public Offering of Common Stock @$1.55/Share
Gamida Cell Ltd. (Nasdaq: GMDA) announced the pricing of a follow-on public offering of 12,905,000 of its ordinary shares at a public offering price of $1.55 per share for aggregate gross proceeds of $20 million, before deducting underwriting discounts and commissions and estimated offering expenses.
Gamida Cell Announces Launch of Public Offering of Ordinary Shares, Size Not Disclosed
Gamida Cell Ltd. (NASDAQ:GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the launch of a follow-on
Gamida Cell Presents Data Demonstrating The Impact Of Transplantation With Omidubicel For Patients With Hematologic Malignancies At 2022 Cord Blood Connect Meeting
- Patients treated with omidubicel reported higher health-related quality of life scores during first-year post-transplant as compared to transplantation with umbilical cord blood (UCB)
- If approved, Omidubicel is
Recap: Gamida Cell Q2 Earnings
Gamida Cell (NASDAQ:GMDA) reported its Q2 earnings results on Monday, August 15, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings Scheduled For August 15, 2022
Companies Reporting Before The Bell
• Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.
Earnings Outlook For Gamida Cell
Gamida Cell (NASDAQ:GMDA) is set to give its latest quarterly earnings report on Monday, 2022-08-15. Here's what investors need to know before the announcement.
Analysts estimate that Gamida Cell will report an earnings per share (EPS) of $-0.29.
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
Gainers
Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.
Recap Of Monday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application…
FDA Accepts Gamida’s Filing For Stem Cell Transplant Candidate Under Priority Review
The U.S. Food and Drug Administration (FDA) has accepted for filing the Gamida Cell’s (NASDAQ: GMDA) Biologics License Application (BLA) for omidubicel in the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant.